Medigus-Backed Polyrizon Develops Technology Potentially Effective Against Influenza Virus

Privately held company Polyrizon Ltd, in which Medigus Ltd MDGS owns 35.86% of share capital, has announced preclinical data for its Capture and Contain (C&C) platform technology.
Related Content: Medigus-Backed Polyrizon's COVID-19 Technology Is Effective Against Coronavirus, Preclinical Study Shows.
The data shows that the technology can reduce the risk of infection with Influenza virus H1N1 and may potentially also treat additional Cold viruses.
Polyrizon tested several formulations of its lead platform against Influenza virus H1N1.
In these studies, the product candidates demonstrated high efficacy by preventing the influenza virus from affecting epithelial host cells and inhibiting cell death.
Polyrizon's new product candidate protects the nasal cavity and the respiratory tract.
Price Action: MDGS shares are up 8.11% at $1.60 during the premarket session on the last check Friday.